Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF-10502-01 in Advanced Solid Tumors and Lymphomas
NCT02661542Phase 2Completed
- Sponsor
- Fujifilm Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Nov 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of 4'-Thio-fac in solid tumor, lymphoma, pancreatic cancer (PC) and 3 more (5 arms), sponsored by Fujifilm Pharmaceuticals. Primary endpoint: Treatment Emergent Adverse Events up to 38 months. Started Jan 2016; status: completed.
02
Drugs
4'-Thio-fac
03
Conditions
solid tumorlymphomapancreatic cancer (PC)cholangiocarcinoma (CCA)gallbladder carcinoma
Beyond the preview
Go deeper on NCT02661542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661542.